# US 2022/0033376 A1 · Estrogen receptor antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033376 A1
- Document ID: US20220033376A1
- Status: Published application
- Kind: A1
- Application number: 17/309,712
- Filed: 2019-12-17
- Published: 2022-02-03
- Earliest claimed: 2018-12-17
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Medshine Discovery Inc.
- Inventors: Shuwen DUAN; Jianyu LU; Lihong HU; Charles Z. DING; Guoping HU; Jian LI; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20220033376A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 35/00: Antineoplastic agents
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 209/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D 401/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

## Claims

### Claim 1

A compound of formula (II), an isomer thereof or a pharmaceutically acceptable salt thereof,
wherein,
X is selected from the group consisting of NH, O and S;
Y is selected from the group consisting of N and CR7;
Y1 is CH, and Y2 is N;
or, Y1 is N, and Y2 is CH or CF;
or, Y1 is CH, and Y2 is CH;
L is
ring A is selected from the group consisting of C6-10 aryl and 5-10 membered heteroaryl;
R1 is selected from the group consisting of H, halogen, CN, COOH, NH2, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl being optionally substituted with 1, 2 or 3 Ra;
R2 is selected from the group consisting of C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl being optionally substituted with 1, 2 or 3 Rb;
R3 is selected from the group consisting of H, halogen, CN, NO2, OH, COOH, NH2, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl being optionally substituted with 1, 2 or 3 Rc;
R13 is H or
R4 is selected from the group consisting of COOH, NH2, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl being optionally substituted with 1, 2 or 3 Rd;
R5 is selected from the group consisting of H, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl being optionally substituted with 1, 2 or 3 Re;
R6, R7, R8 and R9 are each independently selected from the group consisting of H, halogen, CN, NO2, OH, COOH, NH2, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl being optionally substituted with 1, 2 or 3 Rf;
R10, R11 and R12 are each independently selected from the group consisting of H, halogen, CN, NO2, OH, COOH, NH2, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl being optionally substituted with 1, 2 or 3 Rg;
Ra, Rb, Re, Rd, Re, Rf and Rg are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, NH2, COOH, C(═O)NH2, C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl and C3-6 cycloalkyl-C1-3 alkyl-, the C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl and C3-6 cycloalkyl-C1-3 alkyl- being optionally substituted with 1, 2 or 3 R;
R is independently selected from the group consisting of F, Cl, Br, I, OH, CN, NH2, COOH, Me, Et, CF3, CHF2, CH2F, NHCH3, and N(CH3)2;
the C1-6 heteroalkyl, 3-6 membered heterocycloalkyl and 5-6 membered heteroaryl each comprise 1, 2, 3 or 4 heteroatoms or heteroatom groups each independently selected from the group consisting of —NH—, —O—, —S—, —O—N═, —C(═O)—O—, —C(═O)—S—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2— and N.

### Claim 2 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein X is selected from NH, O and S; Y is selected from the group consisting of CR7; Y1 is CH and Y2 is N, or, Y1 is N and Y2 is CH; L is
R13 is

### Claim 3 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein Ra, Rb, Re, Rd, Re, Rf and Rg are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, NH2, COOH, C(═O)NH2, C1-6 alkyl, C1-6 heteroalkyl and cyclopropyl, the C1-6 alkyl, C1-6 heteroalkyl and cyclopropyl being optionally substituted with 1, 2 or 3 R.

### Claim 4 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from the group consisting of phenyl and 5-6 membered heteroaryl.

### Claim 5 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is selected from the group consisting of H, F, Cl, Br, I, CN, COOH, NH2, C1-3 alkyl and C1-3 heteroalkyl, the C1-3 alkyl and C1-3 heteroalkyl being optionally substituted with 1, 2 or 3 Ra.

### Claim 6 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R2 is selected from the group consisting of C1-3 alkyl and C1-3 heteroalkyl, the C1-3 alkyl and C1-3 heteroalkyl being optionally substituted with 1, 2 or 3 Rb.

### Claim 7 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is selected from the group consisting of H and C1-6 alkyl.

### Claim 8 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R4 is selected from the group consisting of COOH, NH2, C1-6 alkyl, —NH—C1-6 alkyl, —N(C1-6 alkyl)2, —C(═O)—O—C1-6 alkyl, —C(═O)—S—C1-6 alkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl and phenyl, the C1-6 alkyl, —NH—C1-6 alkyl, —N(C1-6 alkyl)2, —C(═O)—O—C1-6 alkyl, —C(═O)—S—C1-6 alkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl and phenyl being optionally substituted with 1, 2 or 3 Rd.

### Claim 9 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R5 is selected from the group consisting of H, C1-3 alkyl and C1-3 heteroalkyl, the C1-3 alkyl and C1-3 heteroalkyl being optionally substituted with 1, 2 or 3 Re.

### Claim 10 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R6, R7, R8 and R9 are H.

### Claim 11 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R10, R11 and R12 are each independently selected from H, F, Cl, Br, I, CN, NO2, OH, COOH, NH2, C1-3 alkyl and C1-3 heteroalkyl, the C1-3 alkyl and C1-3 heteroalkyl being optionally substituted with 1, 2 or 3 Rg.

### Claim 12 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit
is selected from

### Claim 13 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit
is selected from the group consisting of

### Claim 14 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein R13 is H,

### Claim 15 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit
is selected from the group consisting of H

### Claim 16 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound, the isomer thereof, or the pharmaceutically acceptable salt thereof is selected from
wherein,
R1, R2, R3, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in claim 1, R41 and R42 are each independently selected from H and C1-6 alkyl, the C1-6 alkyl being optionally substituted with 1, 2 or 3 Rd,
Rd being as defined in claim 1.

### Claim 17 (depends on 1)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from:

### Claim 18 (depends on 17)

The compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 17, wherein the compound is selected from:

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method for treating estrogen receptor positive breast cancer, comprising administering a therapeutically effective amount of the compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, or the pharmaceutical composition thereof.
